Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546055 | 0.79 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL23073838 | 0.77 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL8330488 | 0.77 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL20441409 | 0.77 | ALDH1A1 (0.37) | TSHRTDP1 | |
| SCHEMBL16229092 | 0.75 | TSHR (0.41) | TSHRTDP1 | |
| SCHEMBL9284655 | 0.75 | DPP4 (0.36) | — | |
| SCHEMBL9695136 | 0.73 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL1679017 | 0.73 | — | — | |
| SCHEMBL11421584 | 0.73 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL14518604 | 0.73 | HTT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220389010-A1 | Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-12-08 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-8883378-B2 | Colored curable composition, color filter and method of producing color filter, solid-state image sensor and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8637215-B2 | Colored curable composition, color filter and method of producing color filter, solid-state image sensor and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20110217636-A1 | COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | TSHR 866/4885TDP1 1640/4885 |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | TSHR 1458/4885TDP1 2142/4885 |
| US-20220389010-A1 | Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same | MAPKAPK5, MAP3K1, MAP4K5 | TSHR 2173/4885TDP1 619/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | TSHR 866/4885TDP1 1640/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | TSHR 866/4885TDP1 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.